Is there a Bearish outlook for Halozyme Therapeutics, Inc. (NASDAQ:HALO) this week?

May 24, 2018 - By Henry Gaston

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment increased to 1.66 in Q4 2017. Its up 0.40, from 1.26 in 2017Q3. It is positive, as 13 investors sold Halozyme Therapeutics, Inc. shares while 45 reduced holdings. 39 funds opened positions while 57 raised stakes. 118.31 million shares or 0.18% less from 118.53 million shares in 2017Q3 were reported.
Rhumbline Advisers invested in 126,811 shares or 0.01% of the stock. Art Advsr Ltd Co has 199,021 shares for 0.18% of their portfolio. Sterling Global Strategies Ltd Co holds 1.88% or 22,000 shares in its portfolio. Moreover, Renaissance Technologies Ltd has 0.02% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 736,600 shares. Pnc Fincl Services Grp Inc accumulated 0% or 39,694 shares. 48,270 were reported by Dupont Cap Management. Schwab Charles Investment Mngmt has 0.01% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). First Quadrant Ltd Partnership Ca holds 0% or 4,757 shares. Thompson Davis Com Incorporated invested in 375 shares. Pictet Asset Mgmt accumulated 2.45M shares. Amer Century Inc stated it has 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Timpani Mngmt Ltd Limited Liability Company holds 1.13% or 155,066 shares in its portfolio. Baker Bros Advsrs Ltd Partnership holds 0.28% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 1.58M shares. Goldman Sachs Gp reported 874,133 shares stake. Prudential Financial holds 0.03% or 909,286 shares in its portfolio.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 6 analysts covering Halozyme (NASDAQ:HALO), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. Halozyme had 8 analyst reports since January 17, 2018 according to SRatingsIntel. Deutsche Bank maintained it with “Buy” rating and $21.0 target in Wednesday, January 24 report. The stock has “Buy” rating by Canaccord Genuity on Wednesday, February 21. The company was downgraded on Friday, May 11 by Barclays Capital. The stock has “Buy” rating by Canaccord Genuity on Monday, May 14. The firm has “Overweight” rating given on Wednesday, February 21 by JP Morgan. BMO Capital Markets maintained it with “Market Perform” rating and $19 target in Thursday, February 22 report. Below is a list of Halozyme Therapeutics, Inc. (NASDAQ:HALO) latest ratings and price target changes.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0

The stock increased 2.85% or $0.52 during the last trading session, reaching $18.76. About 484,077 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.10% since May 24, 2017 and is uptrending. It has outperformed by 20.55% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.69 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It has a 41.69 P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Another recent and important Halozyme Therapeutics, Inc. (NASDAQ:HALO) news was published by Seekingalpha.com which published an article titled: “Premarket analyst action – healthcare” on May 11, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: